Belvarafenib Explained

Drug Name:	Belvarafenib
Routes Of Administration:	By mouth
Cas Number:	1446113-23-0
Pubchem:	89655386
Iuphar Ligand:	11544
Chemspiderid:	64878400
Unii:	31M3WLJ3KG
Chembl:	3977543
Synonyms:	HM95573GDC5573RG6185
Iupac Name:	4-amino-N-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide
C:	23
H:	16
Cl:	1
F:	1
N:	6
O:	1
S:	1
Smiles:	CC1=C(C2=C(C=C1)C(=NC=C2)NC3=C(C(=CC=C3)Cl)F)NC(=O)C4=CSC5=C4N=CN=C5N
Stdinchi:	InChI=1S/C23H16ClFN6OS/c1-11-5-6-13-12(7-8-27-22(13)30-16-4-2-3-15(24)17(16)25)18(11)31-23(32)14-9-33-20-19(14)28-10-29-21(20)26/h2-10H,1H3,(H,27,30)(H,31,32)(H2,26,28,29)
Stdinchikey:	KVCQTKNUUQOELD-UHFFFAOYSA-N

Belvarafenib (developed by Hanmi Pharmaceuticals and Genentech) is a small molecule RAF dimer (type II) inhibitor^[1] which shows anti-tumor clinical activity in cancer patients with BRAFV600E- and NRAS- mutations.^[2]

Notes and References

1. Awada G, Neyns B . Melanoma with genetic alterations beyond the BRAFV600 mutation: management and new insights . Current Opinion in Oncology . 34 . 2 . 115–122 . March 2022 . 35050937 . 10.1097/CCO.0000000000000817 . free .
2. Kim TW, Lee J, Shin SJ, Kim JS, Kim YJ, Han HS, Lee SJ, Lim HS, Hong YH, Noh YS, Kyoung Y . Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS mutations: Phase I study. . 31 May 2019 . 10.1200/JCO.2019.37.15_suppl.3000 . Journal of Clinical Oncology . 37 . 15 suppl . 3000 .